SYRE: Advancing innovative antibody combinations for autoimmune diseases with pivotal data expected in 2027
The company is advancing best-in-class antibody therapies for autoimmune diseases, with a focus on IBD and expansion into rheumatic and dermatologic indications. Strong recent data, a robust financial position, and a differentiated co-formulation strategy support multiple upcoming readouts and pote…